澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bendamustine hydrochloride, quantity: 25 mg - injection, powder for - excipient ingredients: mannitol - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c). efficacy relative to first-line therapies other than chlorambucil has not been established.,previously untreated indolent cd20-positive, stage iii-iv non-hodgkin?s lymphoma, in combination with rituximab.,previously untreated cd20-positive, stage iii-iv mantle cell lymphoma in combination with rituximab, in patients ineligible for autologous stem cell transplantation.,relapsed/refractory indolent non-hodgkin?s lymphoma.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bendamustine hydrochloride, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c). efficacy relative to first-line therapies other than chlorambucil has not been established.,previously untreated indolent cd20-positive, stage iii-iv non-hodgkin?s lymphoma, in combination with rituximab.,previously untreated cd20-positive, stage iii-iv mantle cell lymphoma in combination with rituximab, in patients ineligible for autologous stem cell transplantation.,relapsed/refractory indolent non-hodgkin?s lymphoma.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - bendamustine hydrochloride monohydrate 104.6mg equivalent to 100 mg bendamustine hydrochloride - powder for injection - 100 mg - active: bendamustine hydrochloride monohydrate 104.6mg equivalent to 100 mg bendamustine hydrochloride excipient: glacial acetic acid mannitol water for injection - indicated as: · first line treatment of chronic lymphocytic leukaemia (binet stage b or c). · previously untreated indolent non-hodgkin's lymphoma and mantle cell lymphoma. bendamustine sandoz should be used in combination with rituximab in cd20 positive patients. · relapsed/refractory indolent non-hodgkin's lymphoma.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - bendamustine hydrochloride monohydrate 26.1mg equivalent to 25 mg bendamustine hydrochloride - powder for injection - 25 mg - active: bendamustine hydrochloride monohydrate 26.1mg equivalent to 25 mg bendamustine hydrochloride excipient: glacial acetic acid mannitol - indicated as: · first line treatment of chronic lymphocytic leukaemia (binet stage b or c). · previously untreated indolent non-hodgkin's lymphoma and mantle cell lymphoma. bendamustine sandoz should be used in combination with rituximab in cd20 positive patients. · relapsed/refractory indolent non-hodgkin's lymphoma.

以色列 - 英文 - Ministry of Health

astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

以色列 - 英文 - Ministry of Health

astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

以色列 - 英文 - Ministry of Health

dor pharmaceutical services ltd., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

以色列 - 英文 - Ministry of Health

dor pharmaceutical services ltd., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - bendamustine hydrochloride - powder for solution for infusion - 100mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - bendamustine hydrochloride - powder for solution for infusion - 25mg